Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Chamber-specific chromatin architecture guides functional interpretation of disease-associated Cis-regulatory elements in human cardiomyocytes.

  PMID 41526351 · PMC12796357 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  Cardiomyocyte (CM)-specific Hi-C data detect substantially more and stronger promoter-interacting domains (PIDs) for CM marker genes than bulk cardiac tissue Hi-C data

  non-failing cardiac nf-lv-cm biological hi-c fluorescence-activated chip-seq

• Modeling nascent transcription from chromatin landscape and structure with CLASTER.

  PMID 41691282 · PMC13011747 · Genome biology · 2026 · 7 claims · 8 setups

  Full-text index only

  CLASTER, a deep neural network combining chromatin landscape tracks and 3D contact maps, accurately predicts kilobasepair-resolution nascent RNA (EU-seq) profiles in a DNA-sequence-agnostic manner

  embryonic mescs chromatin k562 eu-seq chip-seq micro-c

• Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.

  PMID 33420019 · PMC7794422 · Nature communications · 2021 · 8 claims · 8 setups

  Has reproduction · 50

  SNAI2 is highly expressed in FN-RMS tumors and cell lines compared to normal tissue

  rms fn-rms fp-rms imr90 rna-seq western immunohistochemistry

• CRISPR-based functional genomics for dissecting therapeutic dependency in primary acute myeloid leukemia samples.

  PMID 41759529 · PMC13036604 · Molecular cell · 2026 · 8 claims · 8 setups

  Full-text index only

  An optimized dual-lentiviral CRISPR-Cas9 knockout system with fluorescent markers, SFFV promoter, and improved sgRNA backbone (LRG2.1) achieves efficient, low-toxicity gene editing in AML PDX and primary patient samples

  aml pdx#2263 molm-13 pdx#062614 crispr pooled domain-focused